UWB Crest

cost-CM1102

Working Groups

 

WG1 (A Casnati)

  • Glycoconjugates for drug/gene delivery
  • Aim: to exploit the use of multivalent protein-carbohydrate interactions to deliver macromolecular drugs (e.g., siRNA, antibodies) into specific cell types

WG2 (R Pieters)

  • Glycoconjugates for Diagnostics
  • Aim: to develop methods for adhesion-based detection of carbohydrate-binding proteins involved in diseases (e.g., antibodies) that are key biomarkers for the diagnosis and prognosis of cancer, heart disease and autoimmune diseases

WG3 (V Kren)

  • Glycoconjugates for use as vaccines / modulators of the immune system
  • Aim: to develop nanoscale glycoconjugates that can activate the innate and adaptive immune responses to protect against infectious diseases or treat existing¬† conditions e.g., cancer

WG4 (A Imberty)

  • Glycoconjugates as anti-pathogenic agents
  • Aim: to develop nanoscale glycoconjugates that can be used to prevent infection by viruses, bacteria and fungi, and to reverse the formation of biofilms that form during persistent infections